Table 2.
Summary of meningioma orthotopic xenograft models.
| Mouse Strain/Age of Injection (Weeks) | Injected Cell Types (WHO Grade)/Numbers/Volume (uL) | Site of Injection | Tumor Take (%) | Treatment | Clinical Results | Year, Reference |
|---|---|---|---|---|---|---|
| Athymic/6 | IOMM-Lee (III); human tumor/106/10 | WM/floor of TF | 85–100 | - | - | 2000, [38] |
| Athymic/6–8 | IOMM-Lee (III)/106/3 | Floor of TF | 100 | Verotoxin | Inhibition of TG | 2002, [26] |
| Athymic/6 | BenMenI (I) | Convexity | 100 | - | - | 2005 [9] |
| Athymic/6–8 | IOMM-Lee (III)/5.105 | Brain | 100 | siRNA | Inhibition of TG | 2006 [39] |
| Athymic/4 | Me3TSC (I)-Me10T (I)/106/5 | Convexity (SDS) |
100 | - | - | 2007, [11] |
| Athymic/3 | CH-157-MN (III); IOMM-Lee (III)/104–106/3 | Floor of TF/SDS convexity | 90 | Lb100 + RT | Increased survival compared to RT alone | 2008, [17] 2018, [40] |
| Athymic/5–6 | IOMM-Lee (III)/5.104/0.5 | Skull base | 100 | Temozolomide | Inhibition of TG Increased survival |
2008, [36] |
| Athymic/5 | KT21-DEP1 loss (III) | Convexity | 100 | - | - | 2010, [41] |
| Athymic/5 | PD grade I/106/10 | Convexity (prefrontal cortex) | 90–100 | Celecoxib | No effect | 2012, [42,43] |
| Athymic/8–10 | IOMM-Lee (III)/2.5 × 105/5 uL | Convexity | 100 | Cliengitide + Radiotherapy Sorafenib Temsirolimus |
Inhibition of TG | 2013, [44,45,46] |
| Athymic/6–8 | BenMen1(I)/106/3 | Skull base | 100 | Histone deacetylase inhibitor AR 42 | Affect cell cycle progression Inhibition of TG |
2013, [47] |
| NOD/SCID/gamma null mouse/8 | IOMM-Lee (III)/5.104/3 | Skull Base (Pgi) | 100 | Peripheral blood mononuclear cells | Inhibition of TG | 2013, [37] |
| Athymic/6–8 | BenMenI (I)- KT21-MG1 (III)/106/5 |
Skull base | 100 | Group 1 Pak inhibitor | Inhibition of TG | 2014, [48] |
| Athymic/NA | PD grade I/106/10 | Convexity | 100 | - | - | 2015, [49] |
| Athymic/5–6 | Primary malignant meningioma NF2-mutant MN3/tumorosphere 50000/3–5 | Convexity | 100 | Oncolytic HSV OS2966 |
Increased survival Increased Survival |
2016, [35] 2019, [50] |
| Athymic/NA | CH-157MN (III) | Convexity | 100 | Hydroxyurea + verapamil | No effect | 2016, [51] |
| Athymic/5–6 | CH-157 MN (III)/5.104/5 uL | Convexity/Skull base | 55–80 | - | - | 2019, [52] |
| Athymic/6–8 | IOMM-Lee (III)/104 | Skull base | 100 | - | - | 2019, [53] |
| Athymic/6 | KT21-MG1/50000/ | Convexity | 100 | Mebendazole + /− Radiotherapy | Inhibition of TG Increased survival |
2019, [54] |
| SCID mice/4–6 | IOMM-Lee (III)/106/3–10 | Skull base | 100 | Ganoderic Acid DM | Inhibition of TG Increased survival |
2019, [55] |
| SCID mice/4–6 | IOMM-Lee (III)- BenMen1 (I) |
Skull base | 100 | Palbiciblib + RT | Inhibition of TG Increased survival |
2020, [56] |
Abbreviations: PD: patient-derived; WM: white matter; TF: temporal fossa; SDS: subdural space; RT: radiotherapy; TG: tumor growth; Pgi: post-glenoid injection; SCID: severe combined immunodeficient; NOD: non-obese diabetic.